<DOC>
	<DOC>NCT00077844</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of non-coronary artery bypass graft (CABG) major and minor bleeding.</brief_summary>
	<brief_title>Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)</brief_title>
	<detailed_description />
	<criteria>INCLUSION CRITERIA Male or nonpregnant female greater than or equal to 18 years of age Undergoing nonemergent single or multiple sites/vessels PCI during the same procedure PCI to be performed with a femoral approach EXCLUSION CRITERIA Known or suspected pregnancy in women of childbearing potential Thrombolytic therapy within the previous 24 hours Undergoing primary PCI for ongoing STsegment elevation myocardial infarction (STEMI) Undergoing rescue PCI after failed thrombolysis Any other elective PCI scheduled within the following 30 days after the index PCI Increased bleeding risk: ischemic stroke within the last year or any previous hemorrhagic stroke, intracranial tumor or aneurysm; recent (&lt;1 month) trauma or major surgery (including bypass surgery); active bleeding Uncontrolled arterial hypertension Recent (&lt;48 hours) or planned spinal/epidural anesthesia or puncture Impaired haemostasis: known International Normalized Ratio (INR) &gt;1.5; past or present bleeding disorder (including congenital bleeding disorders such as von Willebrand's disease or hemophilia, acquired bleeding disorders, and unexplained clinically significant bleeding disorders), thrombocytopenia (platelet count &lt;100,000/ÂµL) History of hypersensitivity or contraindication to heparin or LMWH Treatment with oral anticoagulant therapy within 72 hours prior to inclusion or current need for vitaminK antagonist therapy Treatment with a direct thrombin inhibitor, low molecular weight heparin, or unfractionated heparin within the 24 hours preceding enrolment Use of abciximab within the previous 7 days or, tirofiban, or eptifibatide within the past 12 hours of index PCI Inability to give informed consent or high likelihood of being unavailable for followup Treatment with other investigational agents or devices within the previous 30 days, planned use of investigational drugs or devices, or previous enrollment in this trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>